Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christodoulos Papadopoulos

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
Current Pharmaceutical Design|May 22, 2020
Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive ReviewMaria Toumpourleka, Dimitrios Patoulias, Alexandra Katsimardou, et al.
The American Journal of Cardiology|January 3, 2022
Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Theodoros Michailidis, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|May 13, 2022
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary DiseaseDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Blood Pressure Monitoring|March 20, 2021
The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysisDimitrios Patoulias, Christodoulos Papadopoulos, Fotios Siskos, et al.
The American Journal of Cardiology|July 25, 2022
Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline AnemiaDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 15, 2020
Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
The American Journal of Cardiology|October 24, 2021
Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection FractionDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Imprialos, et al.
Kardiologia Polska|May 28, 2020
Postdischarge antidiabetic treatment in patients with type 2 diabetes and acute coronary syndrome: time for a change?Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, et al.
The American Journal of Cardiology|October 12, 2020
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and AlbuminuriaDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, et al.
Endocrinology and Metabolism (Seoul, Korea)|February 10, 2022
Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes MellitusDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Current Pharmaceutical Design|May 22, 2020
Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive ReviewMaria Toumpourleka, Dimitrios Patoulias, Alexandra Katsimardou, et al.
The American Journal of Cardiology|January 3, 2022
Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Theodoros Michailidis, Christodoulos Papadopoulos, et al.
The American Journal of Cardiology|May 13, 2022
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary DiseaseDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Blood Pressure Monitoring|March 20, 2021
The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysisDimitrios Patoulias, Christodoulos Papadopoulos, Fotios Siskos, et al.
The American Journal of Cardiology|July 25, 2022
Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline AnemiaDimitrios Patoulias, Christodoulos Papadopoulos, Nikolaos Fragakis, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 15, 2020
Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
The American Journal of Cardiology|October 24, 2021
Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection FractionDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Imprialos, et al.
Kardiologia Polska|May 28, 2020
Postdischarge antidiabetic treatment in patients with type 2 diabetes and acute coronary syndrome: time for a change?Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, et al.
The American Journal of Cardiology|October 12, 2020
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and AlbuminuriaDimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, et al.
Endocrinology and Metabolism (Seoul, Korea)|February 10, 2022
Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes MellitusDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Pageof 13